PurchasingPolicy.orgPURCHASINGPOLICYBETA
← Back to Influence Map

Medications for the Treatment of Opioid Use Disorder

introduced

This final rule modifies and updates certain provisions of regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health Emergency (PHE) permanent, as well as expanding access to care and evidence-based treatment for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the "Consolidated Appropriations Act, 2023".

No lobbying positions or financial data recorded for this regulation yet.

Public comment data and advocacy positions are added as they become available.